News Stories

The University of Arizona has formally affiliated with St. Joseph’s Hospital and Medical Center/ Dignity Health to develop a cancer care program in Phoenix.

Have you been told by your doctor that you have Actinic Keratoses? The UA Cancer Center has a study aimed at understanding the biology and treatment of skin cancer and you could help.

On Monday afternoon, the National Cancer Institute released its Annual Report to the Nation on the Status of Cancer, the most comprehensive and detailed report of its kind with regard to cancer trends.

University of Arizona Cancer Center researcher Robert Karn, PhD, was awarded the Mendel Memorial Medal for his support of the new Mendelianum in Brno, Czech Republic, and for supporting Czech genetic science over the past decade.

University of Arizona postdoctoral research fellow Tomas Nuño, PhD, will use a $325,000 National Cancer Institute Center to Reduce Cancer Health Disparities to study cancer outcomes among underserved populations.

The Arizona Board of Regents has approved construction of the UA Cancer Center - Phoenix on the Phoenix Biomedical Campus. Construction will begin later this month in downtown Phoenix. 

UACC researcher Paloma Beamer, PhD, has been named to the Arizona Daily Star's "40 Under 40" young leaders for 2012.

The good news: far more people are surviving cancer now than at any other point in history. However, this increase in survivorship has created a new set of medical problems that researchers such as Abraham Jacob, MD, are attempting to resolve.

Lois J. Loescher, PhD, RN, FAAN, has been inducted as a Fellow in the American Academy of Nursing (AAN). Dr. Loescher has spent her career conducting cancer-prevention research and program development, particularly for skin cancer, the most common cancer diagnosed in the United States.

The University of Arizona Cancer Center (UACC) and the Steele Children’s Research Center have announced their collaboration with Immunovative Therapies, Ltd. (ITL) to begin clinical trials using AlloStim™ and AlloVax™, with an initial focus on adult and pediatric leukemias and childhood cancers.